Want to see RCUS full AI Analyst Report?
RCUS Stock Chart & Stats
$24.25
-$0.04(-0.26%)
At close: 4:00 PM EST
$24.25
-$0.04(-0.26%)
Day’s Range― - ―
52-Week Range$8.84 - $31.74
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.41M
Market Cap
$3.44B
Enterprise Value$2.00K
Total Cash (Recent Filing)$822.00M
Total Debt (Recent Filing)$113.00M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 12, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.17
Shares Outstanding125,773,160
10 Day Avg. Volume801,633
30 Day Avg. Volume1,408,584
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)4.06
Price to Sales (P/S)10.36
P/FCF Ratio-5.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.75Price Target Upside51.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$86.14M
Bulls Say, Bears Say
Bulls Say
Cash RunwayA substantial cash balance and multi-year runway provide durable funding to complete registrational trials and planned readouts without immediate financing. This reduces near-term dilution risk, supports prioritized programs, and gives management optionality to time partnerships or non-dilutive deals strategically.
Clinical Differentiation (cascadifan PFS)A materially longer PFS in late-line data signals meaningful clinical differentiation, strengthening registrational positioning, payer negotiations, and commercial uptake potential. Durable efficacy benefits long-term market share and pricing power if Phase 3 confirms these results, underpinning the drug's strategic value.
Focused Portfolio And Spend PrioritizationConcentrating capital and resources on the highest-value asset improves the odds of late-stage success and extends cash runway. Lower overall R&D spend and headcount reductions signal disciplined capital allocation, which can materially reduce structural burn and preserve optionality for commercialization or partnerships.
Bears Say
Sustained Negative Cash FlowPersistently large negative operating and free cash flow creates a structural need for external financing until commercial revenue or sustained cost reductions materialize. Ongoing burn increases dilution risk, constrains strategic flexibility, and makes execution dependent on trial success or partner funding over the medium term.
Large Sustained Losses And Fading RevenueDeep operating losses despite high gross margins indicate the business is far from self-funding. Modest, slightly declining revenue trends erode the cushion against continued R&D spend and weaken the equity base. Without successful commercialization, negative margins and shrinking equity risk long-term financial strain.
Late-stage Discontinuation And Partnership ResetA Phase 3 futility stop and a partner’s decision not to extend option rights reduce external development funding, milestone prospects, and co-development optionality. This shrinks program optionality, shifts more execution risk onto Arcus, and may require reallocating capital to replace lost partnership resources.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences’s price range in the past 12 months?
Arcus Biosciences lowest stock price was $8.84 and its highest was $31.73 in the past 12 months.
What is Arcus Biosciences’s market cap?
Arcus Biosciences’s market cap is $3.44B.
When is Arcus Biosciences’s upcoming earnings report date?
Arcus Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 24 days.
How were Arcus Biosciences’s earnings last quarter?
Arcus Biosciences released its earnings results on May 05, 2026. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.14.
Is Arcus Biosciences overvalued?
According to Wall Street analysts Arcus Biosciences’s price is currently Undervalued.
Does Arcus Biosciences pay dividends?
Arcus Biosciences does not currently pay dividends.
What is Arcus Biosciences’s EPS estimate?
Arcus Biosciences’s EPS estimate is -0.89.
How many shares outstanding does Arcus Biosciences have?
Arcus Biosciences has 125,773,160 shares outstanding.
What happened to Arcus Biosciences’s price movement after its last earnings report?
Arcus Biosciences reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -0.23%.
Which hedge fund is a major shareholder of Arcus Biosciences?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.75 (51.55% Upside)
$36.75 (51.55% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 394.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.55%
12-Months-Change
Fundamentals
Return on Equity
-68.97%
Trailing 12-Months
Asset Growth
-13.75%
Trailing 12-Months
Company Description
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
RCUS Stock 12 Month Forecast
Average Price Target
$36.75
▲(51.55% Upside)
Technical Analysis
Ownership Overview
4.39% Insiders
14.74% Mutual Funds
0.12% Other Institutional Investors
60.90% Public Companies and
Individual Investors